Highly contagious in nature, the influenza virus is an RNA virus capable of causing acute respiratory disease and epidemics in human populations.
The World Health Organization (WHO) states that influenza causes one billion infections and approximately 290,000–650,000 deaths around the world each year. The most effective strategy in preventing influenza virus infection and serious complications is vaccination.
However, the dominant strains vary year on year, as influenza viruses are prone to mutation. As such, each year, vaccine manufacturers have to develop and produce a new influenza vaccine, using recommendations from WHO on specific strains.
Sino Biological provides vaccine manufacturers with complete influenza vaccine development services and production solutions. It offers a range of influenza virus research reagents, such as influenza vaccine antigens, neutralizing antibodies, antibody pairs, and kits. In addition, it can provide high-quality technical services, including kit development, antibody development, and antigen expression.
These services and products are suitable for a number of vaccine development scenarios, for example, candidate vaccine strain screening, vaccine safety and immunogenicity assessment, virus seed batch preparation, and vaccine protective efficacy evaluation.
Influenza vaccine types and manufacturing process
Three main types of influenza vaccines are available globally: live attenuated vaccines, inactivated vaccines, and recombinant vaccines. Currently, inactivated vaccines are most commonly used, and the general manufacturing process includes these steps:
Basic Process of Influenza Vaccine Manufacturing (doi: 10.1186/s12929-020-0626-6). Image Credit: Sino Biological US Inc.
- Virus banking: Manufacturers receive original virus seeds from the WHO and prepare master and working seed lots for production.
- Virus mass production: The viral seed lots are then inoculated into chicken embryos, MDCK cells, or Vero cells to enable viral replication. This process facilitates the production of allantoic fluid (in the case of embryos) or a cell supernatant containing live virus.
- Virus stock preparation: The virus-containing fluids then go through purification steps, including chromatography, centrifugation, and filtration, resulting in a high-purity virus stock. After purification, the virus is then inactivated.
- Vaccine stock preparation: The inactivated virus is then further processed with steps that include lysis, sterile filtration, and purification to create a highly pure vaccine stock.
- Formulation and filling: After purifying the antigen, the vaccine stock is diluted to the appropriate concentration and filled as the finished vaccine. This step involves formulation to ensure the sterility and stability of the vaccine.
Sino Biological offers comprehensive solutions for influenza vaccine development and production to vaccine manufacturers. We provide a wide range of influenza virus research reagents, including influenza vaccine antigens, antibody pairs, neutralizing antibodies, and kits. Additionally, we offer high-quality technical services such as kit development, antigen expression, and antibody development. These products and services are suitable for various vaccine development scenarios, such as candidate vaccine strain screening, virus seed batch preparation, vaccine safety, and immunogenicity assessment.
About Sino Biological Inc.
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.
Sino Biological's core business
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and produced. In addition, we offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Our product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for us to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.